Next Article in Journal
An Imaging Plane Calibration Method for MIMO Radar Imaging
Previous Article in Journal
On-line Smoothing and Error Modelling for Integration of GNSS and Visual Odometry
Previous Article in Special Issue
Detection of Marker miRNAs, Associated with Prostate Cancer, in Plasma Using SOI-NW Biosensor in Direct and Inversion Modes
Open AccessArticle

Thrombin Aptamer-Modified Metal–Organic Framework Nanoparticles: Functional Nanostructures for Sensing Thrombin and the Triggered Controlled Release of Anti-Blood Clotting Drugs

1
Institute of Chemistry, Center for Nanoscience and Nanotechnology, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
2
Institute of Life Science, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
*
Author to whom correspondence should be addressed.
Sensors 2019, 19(23), 5260; https://doi.org/10.3390/s19235260
Received: 26 September 2019 / Revised: 14 November 2019 / Accepted: 23 November 2019 / Published: 29 November 2019
(This article belongs to the Special Issue Electrochemical DNA Sensors)
This paper features the synthesis of thrombin-responsive, nucleic acid-gated, UiO-68 metal–organic framework nanoparticles (NMOFs) loaded with the drug Apixaban or rhodamine 6G as a drug model. Apixaban acts as an inhibitor of blood clots formation. The loads in the NMOFs are locked by duplex nucleic acids that are composed of anchor nucleic acids linked to the NMOFs that are hybridized with the anti-thrombin aptamer. In the presence of thrombin, the duplex gating units are separated through the formation of thrombin–aptamer complexes. The unlocking of the NMOFs releases the drug (or the drug model). The release of the drug is controlled by the concentration of thrombin. The Apixaban-loaded NMOFs revealed improved inhibition, as compared to free Apixaban, toward blood clot formation. This is reflected by their longer time intervals for inducing clot formation and the decreased doses of the drug required to affect clots formation. The beneficial effects of the Apixaban-loaded NMOFs are attributed to the slow-release mechanism induced by the NMOFs carriers, where the inhibition of factor Xa in the blood clotting cycle retards the formation of thrombin, which slows down the release of the drug. View Full-Text
Keywords: Factor Xa; switch; nanomedicine; DNA-nanotechnology; sensor Factor Xa; switch; nanomedicine; DNA-nanotechnology; sensor
Show Figures

Figure 1

MDPI and ACS Style

Chen, W.-H.; Karmi, O.; Willner, B.; Nechushtai, R.; Willner, I. Thrombin Aptamer-Modified Metal–Organic Framework Nanoparticles: Functional Nanostructures for Sensing Thrombin and the Triggered Controlled Release of Anti-Blood Clotting Drugs. Sensors 2019, 19, 5260.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop